- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03198949
A Study Investigating the Anti-epileptic Efficacy of Afinitor (Everolimus) in Patients With Refractory Seizures Who Have Focal Cortical Dysplasia Type II (FCD II)
A Prospective, Randomized, Double-blind, Placebo-controlled Cross Over Study Investigating the Anti-epileptic Efficacy of Afinitor (Everolimus) in Patients With Refractory Seizures Who Have Focal Cortical Dysplasia Type II (FCD II)
This is a prospective, randomized, double-blind, placebo-controlled cross over study designed to evaluate the efficacy and safety of everolimus (trough 5-15 ng/mL) given as adjunctive therapy in patients with focal cortical dysplasia type II who already failed more than two antiepileptic drugs and surgery.
This study will assess the impact of everolimus to placebo on seizure frequency in focal cortical dysplasia type II. The number of patients who experience seizure reduction of 50% or more will be counted during last 4 weeks of each core phase.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a prospective, randomized, double-blind, placebo-controlled cross over study to evaluate the efficacy and safety of everolimus (trough 5-15 ng/mL) given as adjunctive therapy in patients with FCDII who already failed more than 2 antiepileptic drugs and surgery.
- Baseline phase (4 weeks, week -4~-1): From Screening Visit (Week -4, V1) to starting titration visit at Week -1 (V2). For baseline seizure frequency calculations, the 4-week prospective period seizure counts will be totaled. Antiepileptic drug use will be assessed, and patients are required to be on a stable dose of AEDs. All patients who meet eligibility criteria will be randomized in a 1:1 ratio to treatment first arm and placebo first arm.
Core phase I (12 weeks, week 0~11) 2.1.Titration I period (4 weeks, week 0~3): Everolimus doses will be 4.5mg/m2 po daily given at first time and then during the 4-week titration period everolimus dose may get adjusted to reach trough concentration of 5 - 15 ng/mL. At week 2 (V3), 3 (V4) pre-dose PK blood samples will be taken for potential dose adjustments.
2.2. Maintenance I period (8 weeks, week 4~11): After the completion of the titration period, the vast majority of patients are expected to continue at their current dose level during the entire 8 week maintenance period. However, the possibility of further titration does still exist, based on the planned pre-dose PK blood samples that will be collected every 4 weeks [week 4(V5) and 8(V6)].
- Core phase II (12 weeks, week 12~23): After the completion of the core phase I, the everolimus first group will be changed to the placebo and the placebo first group will take everolimus. Dose titration method is same with core phase I.
- Unblinded extension phase (29 weeks, week 24-52): After approval, all enrolled patients will be offered the opportunity to enter the unblinded extension phase of the study at the end of week 23 and continue everolimus. Everolimus will be provided to every study patient during the extension phase of 29 weeks. During the extension phase Everolimus doses will be titrated based on pre-dose PK blood samples at week 24 (V12), 28 (V13), 40 (V14), seizure frequency and everolimus tolerability. At week 52 (V15), the final analysis which include serum and CSF PK studies will be performed.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Seoul, Korea, Republic of
- Yonsei University Healthcare System, Severance Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female between the ages of 4 and 40
- Pathologically confirmed Focal Cortical Dysplasia type II (FCDII)
- Refractory seizure in spite of at least 2 antiepileptic drugs (AEDs) and surgery
- Subjects must have experienced at least 3 seizure events per month for two months retrospectively among 3 months prior to the baseline period in spite of using 1 AED or more.
- Must be at least one antiepileptic drug at a stable dose for at least 4 weeks at the start of the 4-week prospective baseline phase, remain on the same regimen throughout the baseline phase.
- VNS and ketogenic diet are allowed. If the patient is using VNS, device stimulator parameters must remain constant throughout the baseline phase. If the patient is on ketogenic diet, the ratio of the diet must remain constant throughout the baseline phase.
- At least 3 seizures throughout the baseline phase.
- Subjects and their legal guardians must have the ability to comprehend the informed consent form and be willing to provide informed consent. For subjects who are too young or unable to comprehend the written consent, a legal guardian who is able to describe and provide an understanding of the informed consent to the subject must sign the consent form on behalf of the subject.
Exclusion Criteria:
- Patients who need hospitalization due to causes not related to FCDII or epilepsy
- Patients who are pregnant or planning on becoming pregnant
- Patients with seizures secondary to causes other than focal cortical dysplasia
- Immunocompromised patients
- Patients who have received prior treatment with a systemic mTOR inhibitor
- Patients who do not follow up last one year
- Patients who do not show EEG abnormalities
- Patients with a history of non-compliance to medical regimens or who are considered potentially unreliable
- Patients with positive HBV Ag
- Patients who receive live vaccination during baseline study
- Patients with a known hypersensitivity to everolimus or other rapamycin-analogues(sirolimus, temsirolimus) or to its excipients
- Patients who have galactose intolerance, Lapp lactase deficiency, glucose-galactose malabsorption, or other genetic problems related to lactose digestion.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: everolimus first arm
All subjects will receive everolimus during Core phase I and placebo during Core phase II.
|
Everolimus doses will be 4.5mg/m2 po daily given at first time and then during the 4-week titration period everolimus dose may get adjusted to reach trough concentration of 5 - 15 ng/mL. (In order to keep the blind, placebo doses will be also adjusted during core phase based on a random scheme of dose changes.) |
Placebo Comparator: placebo first arm
All subjects will receive placebo during Core phase I and everolimus during Core phase II.
|
Everolimus doses will be 4.5mg/m2 po daily given at first time and then during the 4-week titration period everolimus dose may get adjusted to reach trough concentration of 5 - 15 ng/mL. (In order to keep the blind, placebo doses will be also adjusted during core phase based on a random scheme of dose changes.) |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The number of patients who experience seizure reduction of 50% or more
Time Frame: Seizure frequency during the last 4 weeks of core phase
|
During last 4 weeks of core phase, to compare the number of patients who experience seizure reduction of 50% or more on trough range (5-15 ng/mL) of everolimus versus placebo in FCD II with drug-resistant epilepsy
|
Seizure frequency during the last 4 weeks of core phase
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
seizure-free days
Time Frame: during last 4 weeks of core phase
|
To evaluate seizure-free days during double-blind treatment with adjunctive everolimus compared with placebo
|
during last 4 weeks of core phase
|
reduction in seizure frequency
Time Frame: during last 4 weeks of core phase
|
To compare the reduction in seizure frequency on trough range (5-15 ng/mL) of everolimus versus placebo in patients with FCD II
|
during last 4 weeks of core phase
|
generalized tonic-clonic seizure-free days
Time Frame: during last 4 weeks of core phase
|
To evaluate generalized tonic-clonic seizure-free days during double-blind treatment with adjunctive everolimus compared with placebo
|
during last 4 weeks of core phase
|
reduction in generalized tonic-clonic seizure frequency
Time Frame: during last 4 weeks of core phase
|
To compare the reduction in generalized tonic-clonic seizure frequency on trough range (5-15 ng/mL) of everolimus versus placebo in patients with FCD II
|
during last 4 weeks of core phase
|
number of patients who experience generalized tonic-clonic seizure reduction of 50% or more
Time Frame: during last 4 weeks of core phase
|
To compare the number of patients who experience generalized tonic-clonic seizure reduction of 50% or more on trough range (5-15 ng/mL) of everolimus versus placebo in FCD II
|
during last 4 weeks of core phase
|
level of everolimus in cerebrospinal fluid (CSF) (ng/mL)
Time Frame: One time measurement of everolimus level in CSF (ng/mL) will be performed after 52 weeks
|
Measure level of everolimus in cerebrospinal fluid (CSF) (ng/mL) and compare the value with level of everolimus in blood (ng/mL) in relation to the percentage of seizure reduction in patients who agree to perform CSF analysis additionally.
We hypothesize that some patients with target blood everolimus level would not respond to everolimus because CSF everolimus level does not proportionally increase.
We aim to find differences in CSF everolimus levels between patients who respond well and patients who respond poorly.
|
One time measurement of everolimus level in CSF (ng/mL) will be performed after 52 weeks
|
level of everolimus in blood (ng/mL)
Time Frame: measurement of everolimus level in blood (ng/mL) will be performed at week 0, 2, 3, 4, 8, 12, 14, 15, 16, 20, 24, 28, 40, and 52
|
To measure the level of everolimus in blood (ng/mL) in relation to the percentage of seizure reduction.
We hypothesize that some patients would not respond to everolimus because everolimus level does not proportionally increase with increased intake of everolimus.
|
measurement of everolimus level in blood (ng/mL) will be performed at week 0, 2, 3, 4, 8, 12, 14, 15, 16, 20, 24, 28, 40, and 52
|
adverse events related to everolimus use
Time Frame: Every week during core phase through regular study visits or call visits from week 0 to week 24. At 28, 40, and 52 during extension phase
|
Every adverse event which occurs during the study will be collected.
CTCAE 4.03 guideline will be used.
Number of patients who discontinue using everolimus will be collected and the number will be compared to the number of patients who discontinue placebo during the same period.
Reasons of early withdrawal will be collected.
|
Every week during core phase through regular study visits or call visits from week 0 to week 24. At 28, 40, and 52 during extension phase
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 4-2017-0299
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Epilepsy and Focal Cortical Dysplasia II
-
University Hospital, Strasbourg, FranceUnknownFocal Epilepsy | Refractory Epilepsy | Focal Cortical DysplasiaFrance
-
The Hospital for Sick ChildrenCompletedEpilepsy | Focal Cortical DysplasiaCanada
-
Great Ormond Street Hospital for Children NHS Foundation...Not yet recruitingEpilepsy | Focal Cortical DysplasiaUnited Kingdom
-
King's College Hospital NHS TrustKing's College London; Danish Epilepsy CentreRecruitingEpilepsy | Focal Cortical DysplasiaUnited Kingdom
-
Fondation Ophtalmologique Adolphe de RothschildRecruitingTuberous Sclerosis | Focal Cortical Dysplasia | Hemimegalencephaly | Refractory Focal Epilepsy | Mild Malformation of Cortical Development With Oligodendroglial Hyperplasia in Epilepsy (MOGHE)France
-
NYU Langone HealthCompletedEpilepsy | Tuberous Sclerosis Complex | Focal Cortical DysplasiaUnited States
-
Neuroelectrics CorporationRecruitingEpilepsy | Seizures | Refractory Epilepsy | Epilepsy, Tonic-Clonic | Epilepsy in Children | Seizures, Focal | Focal SeizureSpain, United States, France, Belgium
-
University College, LondonUniversity of LiverpoolTerminatedCortical DysplasiaUnited Kingdom, France, Austria, United States, Czechia, Germany, Italy, Switzerland
-
UCB Biopharma S.P.R.L.PRA Health SciencesCompletedHighly Drug-resistant Focal EpilepsyBelgium, Bulgaria, Germany, Hungary, Netherlands, Spain
-
UCB Biopharma SRLTerminatedAn Open-label Extension Study of UCB0942 in Adult Patients With Highly Drug-resistant Focal EpilepsyHighly Drug-resistant Focal EpilepsyBelgium, Bulgaria, Germany, Hungary, Netherlands, Spain
Clinical Trials on Afinitor (everolimus)
-
Guangdong Provincial People's HospitalNovartisUnknownNeuroendocrine Tumors | Carcinoid TumorChina
-
Queen Mary University of LondonAstraZeneca; Cancer Research UKTerminatedMetastatic Clear Cell Renal CarcinomaUnited Kingdom
-
NYU Langone HealthNovartis Pharmaceuticals; The Children's Tumor FoundationCompletedNeurofibromatosis Type IIUnited States
-
Novartis PharmaceuticalsTerminatedHepatocellular CarcinomaHong Kong, Taiwan, Thailand
-
German Breast GroupNovartisTerminatedMetastatic Breast CancerGermany
-
Novartis PharmaceuticalsNo longer availableAdvanced Hormone Receptor Positive (HR+) Breast Cancer
-
AIO-Studien-gGmbHNovartis Pharmaceuticals; Assign Data Management and Biostatistics GmbHCompletedNeuroendocrine Carcinoma, Grade 3 | Poorly Differentiated Malignant Neuroendocrine Carcinoma | Neuroendocrine Carcinoma, Grade 1 [Well-differentiated Neuroendocrine Carcinoma] That Switched to G3 | Neuroendocrine Carcinoma, Grade 2 [Moderately Differentiated Neuroendocrine Carcinoma]... and other conditionsGermany
-
Novartis PharmaceuticalsCompleted
-
Hopital FochCompleted
-
Dana-Farber Cancer InstituteM.D. Anderson Cancer Center; Massachusetts General Hospital; Novartis; MOUNT SINAI...Completed